Novavax Inc (NVAX): Gary C Evans , director of Novavax Inc sold 50,000 shares on May 23, 2016. The Insider selling transaction was reported by the company on May 25, 2016 to the Securities and Exchange Commission. The shares were sold at $5.41 per share for a total value of $270,371.09 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Feb 1, 2016, John Trizzino (SVP, Commercial Operations) purchased 5,855 shares at $3.63 per share price.On Feb 1, 2016, John A Iii Herrmann (SVP, General Counsel) purchased 2,072 shares at $4.38 per share price.Also, On Feb 1, 2016, Gregory M Glenn (SVP, Research and Development) purchased 2,369 shares at $4.38 per share price.On Feb 1, 2016, Barclay A Phillips (CFO) purchased 405 shares at $4.38 per share price.
Novavax: On Friday, May 20, 2016 heightened volatility was witnessed in Novavax which led to swings in the share price. The shares opened for trading at $5.11 and hit $5.245 on the upside , eventually ending the session at $5.24, with a gain of 2.75% or 0.14 points. The heightened volatility saw the trading volume jump to 38,25,131 shares. The 52-week high of the share price is $15.01 and the company has a market cap of $1,418,903 M . The 52-week low of the share price is at $4.075.
Company has been under the radar of several Street Analysts.Novavax is Initiated by Chardan Capital Markets to Neutral and the brokerage firm has set the Price Target at $5.75. The Rating was issued on Apr 4, 2016.
Novavax Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Company’s product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV) seasonal influenza pandemic influenza and the Ebola virus (EBOV). The Company’s lead adjuvant for human applications Matrix-M is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases including Middle East respiratory syndrome (MERS).